Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Dose Escalation, Multi-center, Open-label Study of HSP990 Administered Orally Once Weekly in Adult Japanese and Korea Patients With Advanced Solid Malignancies

NCT01064089 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT01064089
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01064089 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Dose Escalation, Multi-center, Open-label Study of HSP990 Administered Orally Once Weekly in Adult Japanese and Korea Patients With Advanced Solid Malignancies
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 1
Overall status
Terminated
Start date
February 28, 2010
Completion date
January 31, 2012
Enrollment
17 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors